Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 1
2010 1
2011 2
2012 9
2013 18
2014 16
2015 10
2016 19
2017 27
2018 18
2019 36
2020 56
2021 130
2022 127
2023 39
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28552437

428 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Burgos-Vargas R, Cardiel M, Xibillé D, Pacheco-Tena C, Pascual-Ramos V, Abud-Mendoza C, Mahgoub E, Rahman M, Fan H, Rojo R, García E, Santana K. Burgos-Vargas R, et al. Reumatol Clin (Engl Ed). 2019 Jan-Feb;15(1):43-53. doi: 10.1016/j.reuma.2017.04.006. Epub 2017 May 25. Reumatol Clin (Engl Ed). 2019. PMID: 28552437 Free article. English, Spanish.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC, Cardiel MH, Citera G, Goecke A, Jaller JJ, Lomonte ABV, Miranda P, Velez P, Xibillé D, Kwok K, Rojo R, García EG. Radominski SC, et al. Reumatol Clin. 2017 Jul-Aug;13(4):201-209. doi: 10.1016/j.reuma.2016.04.010. Epub 2016 Jun 15. Reumatol Clin. 2017. PMID: 27317492 Free article. English, Spanish.
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Chopra A, Shobha V, Chandrashekara S, Veeravalli SCM, Sharma R, Rao UR, Pandya S, Wagh S, Kadel JK, Thorat AV, Adhav C, Santos Estrella P, Yu W, Kwok K, Wouters A. Chopra A, et al. Int J Rheum Dis. 2020 Jul;23(7):882-897. doi: 10.1111/1756-185X.13853. Epub 2020 Jun 1. Int J Rheum Dis. 2020. PMID: 32478474 Free PMC article.
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S. Wollenhaupt J, et al. Arthritis Res Ther. 2019 Apr 5;21(1):89. doi: 10.1186/s13075-019-1866-2. Arthritis Res Ther. 2019. PMID: 30953540 Free PMC article. Clinical Trial.
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators. van der Heijde D, et al. Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24. Arthritis Rheumatol. 2019. PMID: 30666826 Free PMC article. Clinical Trial.
428 results